Xochitl Romo-Sandoval

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis	2019	Huseyin Naci Courtney Davis Jelena Savović Julian P. T. Higgins Jonathan A C Sterne Bishal Gyawali Xochitl Romo-Sandoval Nicola Handley Christopher M. Booth

Common Coauthors

Coauthor	Papers Together
Jonathan A C Sterne	1
Jelena Savović	1
Julian P. T. Higgins	1
Bishal Gyawali	1
Courtney Davis	1
Huseyin Naci	1
Christopher M. Booth	1
Nicola Handley	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	The Strength of Association Between Surrogate End Points and Survival in Oncology	2015	Vinay Prasad Chul Kim Mauricio Burotto Andrae Vandross	1
+ PDF Chat	Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool	2013	Mark Corbett Julian P. T. Higgins Nerys Woolacott	1
+	Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials	2012	Jelena Savović Hayley E. Jones Douglas G. Altman Ross Harris Peter Jüni Julie Pildal Bodil Als‐Nielsen Ethan M. Balk Christian Gluud Lise Lotte Gluud	1
+	Allocation concealment in randomised trials: defending against deciphering	2002	Kenneth F. Schulz David A. Grimes	1
+	Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?	2011	Francesco Pignatti Rob Hemmings Bertil Jönsson	1
+ PDF Chat	Evidence of comparative efficacy should have a formal role in European drug approvals	2011	Corinna Sorenson Huseyin Naci Jonathan Cylus Elías Mossialos	1
+	Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials	1995	Klaus‐Peter Schulz	1
+ PDF Chat	Methods of Blinding in Reports of Randomized Controlled Trials Assessing Pharmacologic Treatments: A Systematic Review	2006	Isabelle Boutron Candice Estellat Lydia Guittet Agnès Dechartres David L. Sackett Asbjørn Hróbjartsson Philippe Ravaud	1
+ PDF Chat	Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials	2009	Suman Bhattacharya Gwen Fyfe Robert J. Gray Daniel J. Sargent	1
+	Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials	2007	Steven N. Goodman	1
+	EMA must improve the quality of its clinical trial reports	2011	Corrado Barbui Cinzia Baschirotto Andrea Cipriani	1
+ PDF Chat	Differential dropout and bias in randomised controlled trials: when it matters and when it may not	2013	Melanie L. Bell Michael G. Kenward Diane L. Fairclough Nicholas J. Horton	1
+	Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?	2011	Eitan Amir Boštjan Šeruga Ryan C. Kwong Ian F. Tannock Alberto Ocaña	1
+ PDF Chat	Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors	2012	Asbjørn Hróbjartsson Ann Sofia Skou Thomsen Frida Emanuelsson Britta Tendal Jørgen Hilden Isabelle Boutron Philippe Ravaud Stig Brorson	1
+	Influence of censoring on conclusions of trials for women with metastatic breast cancer	2015	Arnoud J. Templeton Olga Ace Eitan Amir Francisco Vera-Badillo Alberto Ocaña Gregory R. Pond Ian F. Tannock	1
+ PDF Chat	Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer	2013	Francisco Vera-Badillo Roman M. Shapiro Alberto Ocaña Eitan Amir Ian F. Tannock	1
+ PDF Chat	Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports	2014	Tom Jefferson Mark Jones Peter Doshi Chris Del Mar Rokuro Hama Matthew Thompson Igho Onakpoya Carl J. Heneghan	1
+ PDF Chat	Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors	2014	Asbjørn Hróbjartsson Ann Sofia Skou Thomsen Frida Emanuelsson Britta Tendal Jeppe Vejlgaard Rasmussen Jørgen Hilden Isabelle Boutron Philippe Ravaud Stig Brorson	1
+	Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding	2007	Asbjørn Hróbjartsson Elisabeth Forfang Mette T. Haahr Bodil Als‐Nielsen Stig Brorson	1
+ PDF Chat	Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?	2007	Christopher M. Booth Ian F. Tannock	1
+ PDF Chat	Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials	2013	Rajeshwari Sridhara Sumithra J. Mandrekar Lori E. Dodd	1
+ PDF Chat	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012	2014	Nicholas S. Downing Jenerius A. Aminawung Nilay D. Shah Harlan M. Krumholz Joseph S. Ross	1
+ PDF Chat	Adverse Event Reporting in Cancer Clinical Trial Publications	2013	Shanthi Sivendran Asma Latif Russell B. McBride Kristian Stensland Juan P. Wisnivesky Lindsay Haines William Oh Matthew D. Galsky	1
+ PDF Chat	Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study	2008	Lesley J. Wood Matthias Egger Lise Lotte Gluud Kenneth F. Schulz Peter Jüni Douglas G. Altman Christian Gluud Richard M. Martin Anthony J G Wood Jonathan A C Sterne	1
+ PDF Chat	Biases in Randomized Trials	2016	Mohammad Alì Mansournia Julian P. T. Higgins Jonathan A C Sterne Miguel A. Hernán	1
+ PDF Chat	Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies	2016	Matthew J. Page Julian P. T. Higgins Gemma Clayton Jonathan A C Sterne Asbjørn Hróbjartsson Jelena Savović	1
+ PDF Chat	Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014	2016	Anthony J. Hatswell Gianluca Baio Jesse A. Berlin Alar Irs Nick Freemantle	1
+	Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials	2016	Segun Bello Helene Moustgaard Asbjørn Hróbjartsson	1
+ PDF Chat	Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?	2016	Joseph C. Del Paggio Biju Azariah Richard Sullivan Wilma M. Hopman Francis V. James S. Roshni Ian F. Tannock Christopher M. Booth	1
+	Relevance of randomised controlled trials in oncology	2016	Ian F. Tannock Eitan Amir Christopher M. Booth Saroj Niraula Alberto Ocaña Boštjan Šeruga Arnoud J. Templeton Francisco Vera-Badillo	1
+ PDF Chat	Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval	2017	Huseyin Naci Olivier J. Wouters Radhika Gupta John P. A. Ioannidis	1
+	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration	2017	Huseyin Naci Katelyn R. Smalley Aaron S. Kesselheim	1
+	European Marketing Authorizations Granted Based on a Single Pivotal Clinical Trial: The Rule or the Exception?	2017	Anne Vinther Morant Henrik Tang Vestergaard	1
+ PDF Chat	Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications	2018	Steven Woloshin Lisa M. Schwartz Pamela J. Bagley Heather B. Blunt Brian White	1
+ PDF Chat	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour	2018	Jianrong Zhang Yiyin Zhang Shiyan Tang Long Jiang Qihua He Lindsey Tristine Hamblin Jiaxi He Zhiheng Xu Jieyu Wu Yaoqi Chen	1
+	Reporting harms more transparently in trials of cancer drugs	2018	Bishal Gyawali Tomoya Shimokata Kazunori Honda Yukio Ando	1
+	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology	2018	Alyson Haslam Spencer Phillips Hey Jennifer Gill Vinay Prasad	1
+ PDF Chat	Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials	2019	Emerson Y. Chen Sunil K. Joshi Audrey Tran Vinay Prasad	1
+ PDF Chat	Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications	2019	Anna Kordecka Ewa Walkiewicz-Żarek Joanna Łapa Ewelina Sadowska Mariusz Kordecki	1
+	Empirical Evidence of Bias	1995	Kenneth F. Schulz	1
+ PDF Chat	Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study	2015	Iosief Abraha Antonio Cherubini F Cozzolino Rita Florio Maria Laura Luchetta Joseph M. Rimland Ilenia Folletti Mattia Marchesi Alessandro Germani Massimiliano Orso	1